Results 51 to 60 of about 2,232,804 (291)

The use of octreotide in pediatric patients: Practical applications for gastrointestinal disorders and beyond: A narrative review

Nutrition in Clinical Practice, EarlyView.
Abstract Somatostatin is a naturally occurring polypeptide hormone that exerts its effect on the gastrointestinal tract by reducing exocrine and endocrine secretion, resulting in decreased motility, gastric emptying, splanchnic blood flow, fat absorption, lymphatic flow, and gallbladder contraction.
Bailey Dunn, Megan Foxe, Kathy Hunter Sprott, Jessica E. Hook, Candi Jump   +4 more
wiley   +1 more source

Society for Endocrinology Clinical Practice Guideline for the Evaluation of Androgen Excess in Women

Clinical Endocrinology, EarlyView.
ABSTRACT Context Androgen excess is common in women and refers to clinical or biochemical evidence of elevated androgenic steroids such as testosterone. It is associated with underlying polycystic ovary syndrome in the majority of cases. However severe androgen excess is less common and may indicate the presence of underlying adrenal or ovarian ...
Yasir S. Elhassan, James M. Hawley, Leanne Cussen, Ali Abbara, Sophie A. Clarke, Punith Kempegowda, Rima K. Dhillon‐Smith, Puja Thadani, Maureen Busby, Lucy Owusu‐Darkwah, Rachel Marrington, W. Colin Duncan, Robert K. Semple, Richard Quinton, Michael W. O'Reilly   +14 more
wiley   +1 more source

Oral Ondansetron Offers Effective Antidiarrheal Activity for Carcinoid Syndrome Refractory to Somatostatin Analogs.

The Oncologist, 2018
OBJECTIVES Somatostatin analogs (SSAs) are standard for symptomatic patients with neuroendocrine tumors (NETs). However, most patients experience tachyphylaxis, and limited options exist for this so-called "refractory carcinoid syndrome." Recently, 5-HT3
B. Kiesewetter, Heying Duan, W. Lamm, A. Haug, P. Riss, A. Selberherr, C. Scheuba, M. Raderer   +7 more
semanticscholar   +1 more source

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues [PDF]

, 2015
In a randomized, double-blind, Phase III study, we compared pasireotide long-acting release (pasireotide LAR) with octreotide long-acting repeatable (octreotide LAR) in managing carcinoid symptoms refractory to first-generation somatostatin analogues ...
Eriksson, B., Fogelman, D.R., Gadbaw, B., Jarzab, B., Li, J., Mahamat, A., Mansoor, W., Morse, M.A., Newell-Price, J., Oeberg, K., Pasieka, J.L., Poon, D., Ramage, J., Swahn, F., Tomassetti, P., Toumpanakis, C., Walter, T., Weber, M.M., Wolin, E.M.   +18 more
core   +3 more sources

Carcinoid Syndrome and Carcinoid Heart Disease as Manifestations of Non-Metastatic Ovarian Neuroendocrine Tumour

Acta Médica Portuguesa, 2017
The carcinoid syndrome is rare but it is associated with carcinoid heart disease in more than a half of the cases. Carcinoid heart disease is typically characterised by morphological and functional modifications of right-sided valves.
Joana Simões-Pereira, Lai Mun Wang, Attila Kardos, Ashley Grossman   +3 more
doaj   +1 more source

Type 2 and type 3 gastric neuroendocrine tumors have high risk of lymph node metastasis: Systematic review and meta‐analysis

Digestive Endoscopy, EarlyView.
Objectives Lymph node metastasis (LNM) is crucial in determining treatment strategies for gastric neuroendocrine tumors (gNETs). While type 3 is considered more aggressive than types 1 and 2 within the clinical subtype of gNETs, the supporting data were insufficient, due to their rarity. We aimed to study the prevalence and risk factors associated with
Yohei Ogata, Waku Hatta, Takeshi Kanno, Masahiro Saito, Xiaoyi Jin, Naoki Asano, Tomoyuki Koike, Akira Imatani, Yuhong Yuan, Atsushi Masamune   +9 more
wiley   +1 more source

Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr 3]octreotate [PDF]

, 2008
Introduction: Receptor radionuclide therapy is a promising treatment modality for patients with neuroendocrine tumors for whom alternative treatments are limited.
Aken, M.O. (Maarten) van, Essen, M. (Martijn) van, Feelders, R.A. (Richard), Herder, W.W. (Wouter) de, Kam, B.L. (Boen), Keizer, B. (Bart) de, Krenning, E.P. (Eric), Kwekkeboom, D. (Dik)   +7 more
core   +1 more source

Hyperhidrosis: don't sweat it

Internal Medicine Journal, EarlyView.
Abstract Hyperhidrosis is an under‐reported and under‐treated condition that causes significant patient morbidity. Secondary causes require consideration, but the vast majority of cases are idiopathic. The condition is encountered by a range of clinicians, including neurologists, dermatologists and endocrinologists, and it pays to be familiar with the ...
Mitchell J. Lycett, Karl Ng
wiley   +1 more source

Complications from carcinoid syndrome: review of the current evidence

ecancermedicalscience, 2016
Patients with well-differentiated neuroendocrine tumours may develop carcinoid syndrome (CS), which is characterised by flushing, abdominal cramps, diarrhoea, and bronchospasms.
J. M. Mota, L. Sousa, R. Riechelmann
semanticscholar   +1 more source

Evaluation of radiological and clinical efficacy of ^{90}Y-DOTATATE} therapy in patients with progressive metastatic midgut neuroendocrine carcinomas [PDF]

, 2009
Background: To evaluate the radiological and clinical therapeutic effectiveness of ^{90}Y-octreotate [DOTATATE] inpatients with progressive somatostatin receptor-positive midgut neuroendocrine carcinomas (GEPNETs).
Buscombe, John R., Cwikła, Jaroslaw B., Jeziorski, Krzysztof G., Mikolajczak, Renata, Nasierowska-Guttmejer, Anna, Pawlak, Dariusz, Sankowski, Artur, Walecki, Jerzy   +7 more
core